All studies
Phase 3RecruitingInterventionalNCT05850689

Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

A Randomized, Double-Blind, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

  • Major Depressive Disorder
I want to take partRefer a patient13 sites in India (7 recruiting) · 69 worldwide

At a glance

Phase
Phase 3
Study type
Interventional
Sponsor
Intra-Cellular Therapies, Inc.
Enrolment target
470
Started
2 May 2023
Main results due (estimated)
5 April 2027
Study ends (estimated)
5 April 2027
Allocation
Randomized
Design
Parallel
Purpose
Treatment
Masking
Triple (participant, investigator, outcomes assessor)
Sites
69 · 13 in India
First posted
9 May 2023
Registry updated
3 November 2026

Can you take part?

  • Ages 18 years to 65 years.
  • Open to any sex.
  • You need the condition being studied. Healthy volunteers are not accepted.

Age groups: adult, older adult.

These are the headline rules. Every study has a longer list, and whether you are eligible is decided by the research team at the site, never by this page.

Read the full eligibility criteria
Inclusion Criteria:

1. Male or female patients between the ages of 18 and 65 years, inclusive;
2. Meets DSM-5 criteria for MDD (MDD with psychotic features will be acceptable) as confirmed by the Investigator or Sponsor-approved rater using the modified Structured Clinical Interview for DSM-5, Clinical Trials Version (SCID-5-CT) and meets all of the following criteria:

   1. The start of the current major depressive episode (MDE) is at least 12 weeks but not more than 18 months prior to Screening;
   2. Has at least moderate severity of illness based on rater-administered MADRS total score ≥ 24 at Screening and at Baseline;
   3. Has at least moderate severity of illness based on CGI-S score ≥ 4 at Screening and at Baseline;
   4. Has a Quick Inventory of Depressive Symptomatology-Self Report-16 item (QIDS-SR-16) score ≥ 14 at Screening and at Baseline;
   5. Has sufficient history and medical record confirmation verifying the ADT and the current MDE is causing clinically significant distress or impairment in social, occupational, or other important areas of functioning.
3. Currently having an inadequate response (less than 50% improvement) to 2 or more ADTs in the current MDE as confirmed by the Investigator using the Antidepressant Treatment Response Questionnaire (ATRQ) and taking at least the minimum effective dose (per package insert) of one of the following antidepressants as monotherapy treatment for at least 6 weeks duration:

   1. citalopram/escitalopram
   2. fluoxetine
   3. paroxetine
   4. sertraline
   5. duloxetine
   6. levomilnacipran/milnacipran (if locally approved for MDD)
   7. venlafaxine/desvenlafaxine
   8. bupropion
   9. vilazodone
   10. vortioxetine

Exclusion Criteria:

1. Within the patient's lifetime, has a confirmed DSM-5 psychiatric diagnosis other than MDD, including:

   1. Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder or other psychotic disorder;
   2. Bipolar Disorder;
2. Within 6 months of Screening, has a confirmed DSM-5 psychiatric diagnosis other than MDD including:

   1. Anxiety disorders such as Panic Disorder or Generalized Anxiety Disorder; Obsessive-compulsive Disorder; Posttraumatic Stress Disorder as primary diagnoses. Note: Anxiety symptoms may be allowed if secondary to MDD, provided these symptoms do not require concurrent treatment;
   2. Eating disorder;
   3. Substance use disorders (excluding nicotine);
   4. Personality disorder of sufficient severity to have a major impact on the patient's psychiatric status;
   5. Within 12 months of Screening, has had any other psychiatric condition (other than MDD) that has been the main focus of treatment;
3. The patient experiences a ≥ 25% decrease in the MADRS total score between Screening and Baseline;
4. The patient experiences a ≥ 25% decrease in the QIDS-SR-16 total score between Screening and Baseline;
5. In the opinion of the Investigator, the patient has a significant risk for suicidal behavior during participation in the study or:

   1. At Screening, the patient scores "yes" on Suicidal Ideation Items 4 or 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) within 6 months prior to Screening, or at Baseline, the patient scores "yes" on Suicidal Ideation Items 4 or 5 since the Screening Visit;
   2. At Screening, the patient has had 1 or more suicide attempts within 2 years prior to Screening;
   3. At Screening or Baseline, the patient scores ≥ 5 on MADRS Item 10 (Suicidal Thoughts), or
   4. The patient is considered to be in imminent danger to him/herself or others.
6. The patient has a first MDE at age 60 years or older.

What this study is about

In the sponsor’s own words, from the registry.

This is a multicenter, randomized, double-blind, placebo-controlled parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) who have an inadequate response to ongoing ADT.

Read the detailed description

The study will be conducted in three periods:

* Screening Period (up to 2 weeks) during which patient eligibility will be assessed. * Double-blind Treatment Period (6 weeks) in which all patients will be randomized to receive placebo or lumateperone 42 mg/day in 1:1 ratio. * Safety Follow-up Period (1 week) in which all patients will return to the clinic for a safety follow-up visit approximately one week after the last dose of study treatment.

Keywords: Adjunctive MDD Therapy

What participants receive

  • Experimental

    Lumateperone 42 mg

    Drug: Lumateperone

  • Placebo comparator

    Placebo

    Drug: Placebo

Interventions

  • LumateperoneDrug

    Lumateperone 42 mg capsules administered orally, once daily

  • PlaceboDrug

    Matching capsules administered orally, once daily

What the study measures

Primary outcomes

  1. Montgomery-Asberg Depression Rating Scale

    The MADRS is a clinician-rated 10 item scale to assess depressive symptoms. Each item is rated on a 7-point scale from 0-6. The total score ranges from 0 to 60 with a higher score indicating increased severity of depressive symptoms.

    Time frame: Day 43

Secondary outcomes

  1. Clinical Global Impression Scale-Severity

    The CGI-S is a clinician-rated scale to assess a patient's overall mental health. The scale ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).

    Time frame: Day 43

Who is running it

Lead sponsor
Intra-Cellular Therapies, Inc.
Sponsor type
Industry
Responsible party
The sponsor
Organisation
Intra-Cellular Therapies, Inc.
Data monitoring committee
No
US FDA-regulated drug
Yes
US FDA-regulated device
No
Sponsor's study ID
ITI-007-505
Other IDs
ITI-007-505
  • Intra-Cellular Therapies, Inc. Clinical Trial

    Study director

    Intra-Cellular Therapies, Inc.

Study sites(69)

  • Baramati Hospital

    Bārāmati, India

    Recruiting

  • S P Medical College And Associated Group of Hospitals

    Bikaner, India

    Recruiting

  • Post Graduate Institute of Medical Education And Research PGIMER

    Chandigarh, India

    Recruiting

  • Swastik Hospital

    Kolhāpur, India

    Recruiting

  • KIMS-Kingsway Hospitals

    Nagpur, India

    Recruiting

  • Divyam Hospital

    Palsāna, India

    Recruiting

  • Shree Samarth Hospital

    Pune, India

    Recruiting

  • Ratandeep Surgical Hospital And Endoscopy Clinic

    Ahmedabad, India

    Suspended

  • Sushrusha Navneet Memorial Hospital

    Ahmedabad, India

    Suspended

  • J L N Medical College and Attached Hospitals

    Ajmer, India

    Suspended

  • Gauhati Medical College and Hospital

    Guwahati, India

    Completed

  • Nagecha Hospital

    Rajkot, India

    Completed

  • Acharya vinoba bhave rural hospital

    Wardha, India

    Suspended

  • University of Alabama at Birmingham

    Huntsville, Alabama, United States

    Recruiting

  • CNRI-Los Angeles, LLC

    Pico Rivera, California, United States

    Recruiting

  • University of Connecticut Health Center

    Farmington, Connecticut, United States

    Recruiting

  • Premier Clinical Research Institute

    Miami, Florida, United States

    Recruiting

  • Miami Jewish Health System

    Miami, Florida, United States

    Recruiting

  • Interventional Psychiatry of Tampa Bay

    Tampa, Florida, United States

    Recruiting

  • The Emory Clinic

    Atlanta, Georgia, United States

    Recruiting

  • CenExeli Research LLC

    Decatur, Georgia, United States

    Recruiting

  • Collective Medical Research

    Overland Park, Kansas, United States

    Recruiting

  • Psychiatric Care and Research Center (PCRC)

    O'Fallon, Missouri, United States

    Recruiting

  • Bio Behavioral Health

    Toms River, New Jersey, United States

    Recruiting

  • SPRI Clinical Trials, LLC

    Brooklyn, New York, United States

    Recruiting

  • Manhattan Behavioral Medicine

    New York, New York, United States

    Recruiting

  • Quest Therapeutics of Avon Lake

    Avon Lake, Ohio, United States

    Recruiting

  • University of Cincinnati Medical Center

    Cincinnati, Ohio, United States

    Recruiting

  • The Ohio State University

    Columbus, Ohio, United States

    Recruiting

  • University of Pennsylvania - Perelman School of Medicine

    Philadelphia, Pennsylvania, United States

    Recruiting

  • DM Clinical Research

    Houston, Texas, United States

    Recruiting

  • Pillar Clinical Research, LLC

    Richardson, Texas, United States

    Recruiting

  • Northwest Clinical Research Center

    Bellevue, Washington, United States

    Recruiting

  • Ambulatory for Individual Practice for Specialized Medical Care in Psychiatry Dr. Ivo Natsov ET

    Cherven Bryag, Bulgaria

    Recruiting

  • Medical Center Lifemed

    Kardzhali, Bulgaria

    Recruiting

  • Medical Center Medconsult-Pleven

    Pleven, Bulgaria

    Recruiting

  • Medical Center Mentalcare OOD

    Plovdiv, Bulgaria

    Recruiting

  • MHC - Sofia, EOOD

    Sofia, Bulgaria

    Recruiting

  • Medical Center Hera EOOD

    Sofia, Bulgaria

    Recruiting

  • Medical Center Intermedica, OOD

    Sofia, Bulgaria

    Recruiting

Showing 40 of 69 sites. 53 recruiting, 12 not recruiting and 4 cancelled; 13 in India. Not recruiting covers sites not yet open, finished enrolling, completed or paused; cancelled covers sites withdrawn before opening or stopped for good.

References and data sharing

Participant data shared
No

Source: ClinicalTrials.gov record NCT05850689, status verified November 2026. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.

Take part

Interested in this study?

Tell us how to reach you and we will connect you with the study team. Or refer someone you care for, with their permission.

A person reads this, not a bot. We are not doctors, this is not medical advice, and it is not for emergencies.

Not the right study?

Every study recruiting in India, one search away.